|Day Low/High||66.81 / 69.78|
|52 Wk Low/High||60.89 / 71.19|
Medicine is a slow business and I view Gilead Sciences as a hold for now.
And why maintaining a small position in defense stocks is important.
And it is happening not a moment too soon.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
Gilead has been trying to turn things around but few see that turn coming anytime soon.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.
It becomes difficult for me to tell you where to run in these markets...
Traders who are already long Gilead should buy more and if you are flat this is a good location to go long.
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Investors might be finally recognizing the hidden value of the firms' drug research and development.
This biotech's weekly chart is very encouraging.
Taking the measure of what's keeping the markets in the dumps.
Markets have perked up just a tad across the board since our last update. As mentioned in an earlier post, Galmed Pharmaceuticals is the second small-cap NASH (nonalcoholic steatohepatitis) play that has soared over the past week. The shares are up ...
The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.
After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.
I think it very possible that there will be a positive reaction tonight, more likely based on what Tim Cook says.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
A look at possible second-quarter M&A activity in the biotech sector.
Your burning biotech questions answered in our latest mailbag.
We'll answer two of the common questions we have received so far in March.
Maybe inverse and/or leveraged positions are perverse in nature.
The biotech sector has seen a big rally, but there are still opportunities.
You mean to tell me if the buyers walked away for 10 minutes they couldn't get these stocks lower?
Outside of oncology, the rare disease area is a good target for M&A in 2018.